It is known that CCL11 is implicated in Th2 inflammatory diseases, and it has recently been reported that CCL11 gene expression can be a predictive marker for ustekinumab response in patients with Crohn’s disease [23]. This evidence concerns the gene CCL11 and Crohn disease.